Elevated liver enzymes in a German tertiary-care hospital: Distribution, diagnostic steps and diagnosis groups

Abstract

Background The determination of liver blood tests is frequently performed in hospitalized patients, and abnormal values require further diagnostics. Yet, analyses considering the management of elevated liver enzymes are missing. Therefore, this study aimed to analyze the distribution of abnormal liver function tests and the subsequent diagnostic steps across different medical specialties.

Methods From our Hannover liver-injury database, we identified 63,300 cases of patients who were hospitalized between January 2008 and July 2021 with AST or ALT > 3 ULN or AP or TBI > 2 ULN at any time point during hospitalization. Of these, 29,547 cases fulfilled the inclusion criteria and were subjected to further analysis. Cases were analyzed according to the three groups: internal medicine, surgery and others. Analyses were performed regarding baseline characteristics, liver-related diagnostics and factors influencing hospital mortality.

Results Elevated liver blood tests were mainly observed in internal medicine (n=17,762, 60.1%), followed by the surgery department 34.2% (n=10,105). Notably, 40.2% (n=11,896) developed liver enzyme elevation above the cut-offs during the hospital stay. Testing for hepatitis B and C was more often performed in the surgery department compared to in internal medicine. In total, 5.6% of the cases (n=1,640) had a liver biopsy. Hyperbilirubinemia (total bilirubine ≥ 2ULN) and AST/ALT ratios >2 were associated with in-hospital mortality.

Conclusion Clinicians are often faced with elevated liver enzymes. However, diagnostic steps differ between different specialties. Physicians should be aware of the increased in-hospital mortality in cases with hyperbilirubinemia or elevated AST/ALT ratios.

Zusammenfassung

Hintergrund Bei hospitalisierten Patienten gehört die Erhebung von Leberwerten zur Routinediagnostik, bei der im Falle einer Erhöhung eine erweiterte Diagnostik erfolgen sollte. Dennoch fehlen Studien zur Verteilung erhöhter Leberwerte in Kliniken und der durchgeführten Diagnostik, was Ziel dieser Studie ist.

Methoden Im Zeitraum von Januar 2008 und Juli 2021 wurden von der Hannoveraner Liver Injury-Datenbank 63 300 Fälle von Patienten, deren Leberwerte im Rahmen eines stationären Aufenthaltes einen der folgenden Grenzwerte überschritten haben, identifiziert: AST oder ALT > 3 ULN oder AP oder TBI > 2 ULN. 29 547 Fälle erfüllten alle Einschlusskriterien und wurden für die Analyse herangezogen. Die Fälle wurden in die Gruppen Innere Medizin, Chirurgie und Andere eingeteilt. Neben den Patientenbasisdaten wurden die diagnostischen Schritte und Faktoren mit Einfluss auf die Mortalität untersucht.

Ergebnisse Erhöhte Leberwerte finden sich hauptsächlich in der Inneren Medizin (n=17 762, 60,1%), gefolgt von der Chirurgie 34,2% (n=10 105). In 40,2% (n=11 896) entwickelten sich erhöhte Leberwerte erst im Rahmen des Aufenthaltes. Eine Testung auf das Hepatitis B- und C-Virus erfolgte häufiger in der Chirurgie als der Inneren Medizin. Eine Leberbiopsie erfolgte in 5,6% der gesamten Fälle (n=1 640). Hyperbilirubinämie (Gesamtbilirubin ≥ 2ULN) oder erhöhte AST/ALT-Quotienten > 2 waren mit einer erhöhten Mortalität assoziiert.

Schlussfolgerung Kliniker sind regelmäßig mit erhöhten Leberwerten konfrontiert. Die Diagnostik, die sie im Rahmen der Abklärung initiieren, variiert zwischen den einzelnen Fachrichtungen. Es sollte nicht außer Acht gelassen werden, dass eine Hyperbilirubinämie sowie ein erhöhter AST/ALT-Quotient in diesem Setting mit einer erhöhten Mortalität einhergeht.

Keywords

elevated liver enzymes - diagnostic approach - distribution - hepatitis

Schlüsselwörter

erhöhte Leberwerte - diagnostisches Vorgehen - Hepatitis - Diagnostik

Publication History

Received: 05 April 2023

Accepted after revision: 03 August 2023

Article published online:
10 January 2024

• References

• 1 Radcke S, Dillon JF, Murray AL. A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes. Eur J Gastroenterol Hepatol 2015; 27: 1-7 DOI: 10.1097/MEG.0000000000000233. (PMID: 25380394)
• 2 Limdi JK and Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J 2003; 79: 307 DOI: 10.1136/pmj.79.932.307. (PMID: 12840117)
• 3 Wedemeyer H, Hofmann WP, Lueth S. et al. ALT screening for chronic liver diseases: scrutinizing the evidence. Z Gastroenterol 2010; 48: 46-55 DOI: 10.1055/s-0028-1109980. (PMID: 20072996)
• 4 Weibrecht K, Dayno M, Darling C. et al. Liver Aminotransferases Are Elevated with Rhabdomyolysis in the Absence of Significant Liver Injury. Journal of Medical Toxicology 2010; 6: 294-300 DOI: 10.1007/s13181-010-0075-9. (PMID: 20407858)
• 5 Thompson PL, Fletcher EE, Katavatis V. Enzymatic indices of myocardial necrosis: influence on short- and long-term prognosis after myocardial infarction. Circulation 1979; 59: 113-119
• 6 Moon J, Kang W, Oh PC. et al. Serum transaminase determined in the emergency room predicts outcomes in patients with acute ST-segment elevation myocardial infarction who undergo primary percutaneous coronary intervention. Int J Cardiol 2014; 177: 442-447
• 7 Barcellini W and Fattizzo B. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia. Dis Markers 2015; 2015: 635670 DOI: 10.1155/2015/635670. (PMID: 26819490)
• 8 Garnero P, Buchs N, Zekri J. et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82: 858-864 DOI: 10.1054/bjoc.1999.1012. (PMID: 10732759)
• 9 Björnsson HK, Olafsson S, Bergmann OM. et al. A prospective study on the causes of notably raised alanine aminotransferase (ALT). Scand J Gastroenterol 2016; 51: 594-600 DOI: 10.3109/00365521.2015.1121516. (PMID: 26653080)
• 10 Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005; 172: 367-379 DOI: 10.1503/cmaj.1040752. (PMID: 15684121)
• 11 Herlong HF. Approach to the Patient with Abnormal Liver Enzymes. Hosp Pract 1994; 29: 32-38
• 12 Lee TH, Kim WR, Poterucha JJ. Evaluation of Elevated Liver Enzymes. Clin Liver Dis 2012; 16: 183-198 DOI: 10.1016/j.cld.2012.03.006. (PMID: 22541694)
• 13 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-276 DOI: 10.1016/0168-8278(90)90124-a. (PMID: 2254635)
• 14 Andrade RJ, Aithal GP, Björnsson ES. et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019; 70: 1222-1261
• 15 M’Kada H, Perazzo H, Munteanu M. et al. Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study. PLoS One 2012; 7: e42418
• 16 Schäfer A, Schöttker-Königer T. Ist meine Therapie wirksam? Testen von Unterschiedshypothesen mit parametrischen Verfahren. In: Schäfer A, Schöttker-Königer T. Statistik Und Quantitative Methoden Für Gesundheitsfachberufe. Berlin, Heidelberg: Springer; 2015: 89-109
• 17 Bortz J. Statistik Für Sozialwissenschaftler, Chapter 5 Verfahren Zur Überprüfung Von Unterschiedshypothesen. Springer-Lehrbuch Springer-Berlin 1989;
• 18 Kwak SG and Kim JH. Central limit theorem: the cornerstone of modern statistics. Korean J Anesthesiol 2017; 70: 144-156 DOI: 10.4097/kjae.2017.70.2.144. (PMID: 28367284)
• 19 Akoglu H. User’s guide to correlation coefficients. Turkish Journal of Emergency Medicine 2018; 18: 91-93 DOI: 10.1016/j.tjem.2018.08.001. (PMID: 30191186)
• 20 Lammers WJ, van Buuren HR, Hirschfield GM. et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147: 1338-1349.e5
• 21 Björnsson E and Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-489 DOI: 10.1002/hep.20800. (PMID: 16025496)
• 22 Andrade RJ, Lucena MI, Fernández MC. et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521 DOI: 10.1016/j.gastro.2005.05.006. (PMID: 16083708)
• 23 De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis: The transaminase serum activities. Clinica Chimica Acta 1957; 2: 70-74 DOI: 10.1016/0009-8981(57)90027-x. (PMID: 13447217)
• 24 Zinellu A, Arru F, De Vito A. et al. The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients. Eur J Clin Invest 2021; 51: e13427 DOI: 10.1111/eci.13427. (PMID: 33043447)
• 25 Ghahari M, Salari A, Ghafoori Yazdi M. et al. Association Between Preoperative De Ritis (AST/ALT) Ratio and Oncological Outcomes Following Radical Cystectomy in Patients With Urothelial Bladder Cancer. Clinical Genitourinary Cancer 2022; 20: e89-e93
• 26 Schupp T, Weidner K, Rusnak J. et al. Diagnostic and prognostic value of the AST/ALT ratio in patients with sepsis and septic shock. Scand J Gastroenterol 2023; 58: 392-402
• 27 Guven HE and Oral S. Liver enzyme alterations after laparoscopic cholecystectomy. J Gastrointestin Liver Dis 2007; 16: 391-394 (PMID: 18193120)
• 28 Sabzi F and Faraji R. Liver Function Tests Following Open Cardiac Surgery. J Cardiovasc Thorac Res 2015; 7: 49-54 DOI: 10.15171/jcvtr.2015.11. (PMID: 26191391)
• 29 Leonhardt S, Veltzke-Schlieker W, Adler A. et al. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Critical Care 2015; 19: 131 DOI: 10.1186/s13054-015-0861-5. (PMID: 25886728)
• 30 Nikolaou M, Parissis J, Yilmaz MB. et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 2013; 34: 742-749 DOI: 10.1093/eurheartj/ehs332. (PMID: 23091203)
• 31 Tsutsumi Y, Yamamoto Y, Ito S. et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015; 7: 2344-2351
• 32 Poethko-Müller C, Zimmermann R, Hamouda O. et al. Die Seroepidemiologie der Hepatitis A, B und C in Deutschland. 2013; 56.
• 33 Faber MS, Wenzel JJ, Jilg W. et al. Hepatitis E virus seroprevalence among adults, Germany. Emerg Infect Dis 2012; 18: 1654-1657 DOI: 10.3201/eid1810.111756. (PMID: 23018055)
• 34 Juhl D, Baylis SA, Blümel J. et al. Seroprevalence and incidence of hepatitis E virus infection in German blood donors. Transfusion 2014; 54: 49-56 DOI: 10.1111/trf.12121. (PMID: 23441647)
• 35 Wiesner R, Edwards E, Freeman R. et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96 DOI: 10.1053/gast.2003.50016. (PMID: 12512033)